Basilea Pharmaceutica AG
BPMUF
$54.00
$1.172.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.76% | 16.62% | -0.44% | 15.14% | 30.58% |
| Total Other Revenue | 91.25% | -31.42% | -72.53% | -70.43% | -69.21% |
| Total Revenue | 35.48% | 12.28% | -9.92% | 2.29% | 13.45% |
| Cost of Revenue | 12.34% | 36.55% | 70.70% | 41.03% | 13.56% |
| Gross Profit | 82.19% | -17.65% | -73.91% | -43.93% | 13.21% |
| SG&A Expenses | 1.81% | 6.54% | 11.58% | 15.51% | 15.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.94% | 29.10% | 54.44% | 34.70% | 14.04% |
| Operating Income | 200.80% | -34.24% | -110.75% | -82.45% | 9.75% |
| Income Before Tax | 542.33% | -24.56% | -126.54% | -106.35% | -12.45% |
| Income Tax Expenses | -188,415.38% | -598,786.21% | -328,267.39% | -29,644.57% | 122.17% |
| Earnings from Continuing Operations | 725.50% | 24.41% | -101.43% | -85.10% | -12.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 725.50% | 24.41% | -101.43% | -85.10% | -12.87% |
| EBIT | 200.80% | -34.24% | -110.75% | -82.45% | 9.75% |
| EBITDA | 181.13% | -31.71% | -107.10% | -77.52% | 16.59% |
| EPS Basic | 713.73% | 22.58% | -101.68% | -85.29% | -12.79% |
| Normalized Basic EPS | 532.99% | -25.74% | -126.50% | -106.28% | -12.37% |
| EPS Diluted | 1,237.01% | 20.87% | -107.12% | -96.04% | -50.60% |
| Normalized Diluted EPS | 856.84% | -30.34% | -130.70% | -115.22% | -48.05% |
| Average Basic Shares Outstanding | 0.82% | 0.89% | 0.96% | 1.03% | 1.10% |
| Average Diluted Shares Outstanding | 7.46% | 3.73% | 0.00% | 3.82% | 7.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
